NEW YORK, April 1, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that data demonstrating SL-501 inhibits the growth of tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia (CML) cells in preclinical models was selected for poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR) Conference, being held April 5-9, 2014 in San Diego, CA. SL-501 is a highly potent targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-501 is a next generation variant of SL-401; SL-401 is currently being advanced in clinical trials of multiple hematologic cancers.
Help employers find you! Check out all the jobs and post your resume.
